Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression by Calcinotto, Arianna, Brevi, Arianna, Chesi, Marta, Ferrarese, Roberto, Garcia Perez, Laura, Grioni, Matteo, Kumar, Shaji, Garbitt, Victoria M., Sharik, Meaghen E., Henderson, Kimberly J., Tonon, Giovanni, Tomura, Michio, Miwa, Yoshihiro, Esplugues, Enric, Flavell, Richard A., Huber, Samuel, Canducci, Filippo, Rajkumar, Vincent S., Bergsagel, P. Leif, Bellone, Matteo

Get full text

Clonal competition with alternating dominance in multiple myeloma by Keats, Jonathan J., Chesi, Marta, Egan, Jan B., Garbitt, Victoria M., Palmer, Stephen E., Braggio, Esteban, Van Wier, Scott, Blackburn, Patrick R., Baker, Angela S., Dispenzieri, Angela, Kumar, Shaji, Rajkumar, S. Vincent, Carpten, John D., Barrett, Michael, Fonseca, Rafael, Stewart, A. Keith, Bergsagel, P. Leif

Get full text

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy by Chesi, Marta, Matthews, Geoffrey M., Garbitt, Victoria M., Palmer, Stephen E., Shortt, Jake, Lefebure, Marcus, Stewart, A. Keith, Johnstone, Ricky W., Bergsagel, P. Leif

Get full text

Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy by Meermeier, Erin W, Welsh, Seth J, Sharik, Meaghen E, Du, Megan T, Garbitt, Victoria M, Riggs, Daniel L, Shi, Chang-Xin, Stein, Caleb K, Bergsagel, Marco, Chau, Bryant, Wheeler, Matthew L, Bezman, Natalie, Wang, Feng, Strop, Pavel, Bergsagel, P Leif, Chesi, Marta

Get full text

SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis by Cheng, Hailing, Liu, Pixu, Wang, Zhigang C, Zou, Lihua, Santiago, Stephanie, Garbitt, Victoria, Gjoerup, Ole V, Iglehart, J Dirk, Miron, Alexander, Richardson, Andrea L, Hahn, William C, Zhao, Jean J

Get full text

Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression by Chesi, Marta, Stein, Caleb K, Garbitt, Victoria M, Sharik, Meaghen E, Asmann, Yan W, Bergsagel, Matteo, Riggs, Daniel L, Welsh, Seth J, Meermeier, Erin W, Kumar, Shaji K, Braggio, Esteban, Bergsagel, P Leif

Get full text

Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma by Welsh, Seth J, Barwick, Benjamin G, Meermeier, Erin W, Riggs, Daniel L, Shi, Chang-Xin, Zhu, Yuan Xiao, Sharik, Meaghen E, Du, Megan T, Abrego Rocha, Leslie D, Garbitt, Victoria M, Stein, Caleb K, Petit, Joachim L, Meurice, Nathalie, Tafoya Alvarado, Yuliza, Fonseca, Rodrigo, Todd, Kennedi T, Brown, Sochilt, Hammond, Zachery J, Cuc, Nicklus H, Wittenberg, Courtney, Herzog, Camille, Roschke, Anna V, Demchenko, Yulia N, Chen, Wei-Dong D, Li, Peng, Liao, Wei, Leonard, Warren J, Lonial, Sagar, Bahlis, Nizar J, Neri, Paola, Boise, Lawrence H, Chesi, Marta, Bergsagel, P Leif

Get full text

Abstract 5622: scRNA-seq reveals restructuring of the immune microenvironment of multiple myeloma following treatment with an IAP antagonist by Stein, Caleb K., Meermeier, Erin, Welsh, Seth, Garbitt, Victoria, Sharik, Meaghen, Bergsagel, P. Leif, Banovich, Nicholas, Keats, Jonathan, Chesi, Marta

Get full text

Identification of Novel Therapeutic Targets in the Clinically Predictive VkMYC Mouse Model of Multiple Myeloma by Chesi, Marta, Garbitt, Victoria, Bergsagel, P. Leif

Get full text

Abstract 5630: Anti-BCMA bispecific tool therapy against VkMYC multiple myeloma is enhanced by IMiDs by Meermeier, Erin W., Sharik, Meaghen E., Welsh, Seth J., Stein, Caleb K., Garbitt, Victoria M., Brown, Sochilt, Todd, Kennedi T., Bergsagel, Marco, Bergsagel, P. Leif, Chesi, Marta

Get full text

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma by Welsh, Seth J, Barwick, Benjamin G, Meermeier, Erin, Riggs, Daniel, Shi, Chang-Xin, Zhu, Yuan Xiao, Sharik, Meaghen E, Du, Megan T, Garbitt, Victoria Marie, Stein, Caleb K, Petit, Joachim L, Meurice, Nathalie, Fonseca, Rodrigo, Todd, Kennedi, Brown, Sochilt, Tafoya Alvarado, Yuliza, Hammond, Zachary, Cuc, Nicklus, Wittenberg, Courtney, Herzog, Camille, Boise, Lawrence H., Bahlis, Nizar J., Neri, Paola, Kuehl, W. Michael, Chesi, Marta, Bergsagel, P. Leif

Get full text

Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma by Welsh, Seth, Riggs, Daniel, Meermeier, Erin, Shi, Chang-Xin, Garbitt, Victoria, Sharik, Meaghen E, Du, Megan, Todd, Kennedi, Hammond, Zachary, Brown, Sochilt, Stein, Caleb K, Neri, Paola, Bahlis, Nizar J., Barwick, Benjamin G, Boise, Larry H., Kuehl, W. Michael, Chesi, Marta, Bergsagel, P. Leif

Get full text

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma by Croucher, Danielle C, Chesi, Marta, Li, Zhihua, Garbitt, Victoria Marie, Sharik, Meaghen E, Waller, Daniel, Sebag, Michael, Bergsagel, P. Leif, Pugh, Trevor J., Trudel, Suzanne

Get full text

Abstract 3015: IMiDs and BET inhibitors target distinct pathways of MYC dysregulation by super-enhancers in multiple myeloma by Riggs, Daniel L., Herzog, Camille, Garbitt, Victoria M., Keane, Niamh, Hillukka, Courtney J., Hammond, Zachary J., Wiedmeier, Julia E., Welsh, Seth J., Tian, Shulan, Yan, Huihuang, Maity, Ranjan, Bahlis, Nizar, Neri, Paola, Kuehl, W Michael, Chesi, Marta, Bergsagel, P Leif

Get full text

Abstract 4628: A clinically relevant mouse model to understand how IMiDs modulate the host-tumor immunolandscape in multiple myeloma by Welsh, Seth J., Sharik, Meaghen E., Garbitt, Victoria M., Taylor, Link R., Riggs, Daniel L., Stein, Caleb, Day, Grady, Hillukka, Courtney J., Hammond, Zach J., Bergsagel, P Leif, Chesi, Marta

Get full text

Mir-15a/16-1 Haploinsufficiency Contributes To Myeloma Progression by Chesi, Marta, Garbitt, Victoria, Palmer, Stephen, Bergsagel, P. Leif

Get full text

IAP Antagonists Are a Novel Class Of Immunomodulators That Induce Complete Response In VkMYC Myeloma By Stimulating Plasmacytoid Dendritic Cells To Secrete IFNa by Chesi, Marta, Garbitt, Victoria, Palmer, Stephen, Bergsagel, P. Leif

Get full text

Dysregulation Of Cyclin D1 Or Activation Of KRAS Accelerate The Development Of Monoclonal Gammopathy and Cooperate To Cause Its Progression by Chesi, Marta, Garbitt, Victoria, Palmer, Stephen, Bergsagel, P. Leif

Get full text

P-177 Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma (MM) by Welsh, Seth, Barwick, Benjamin, Meermeier, Erin, Riggs, Daniel, Shi, Chang-Xin, Sharik, Meaghen, Du, Megan, Rocha, Leslie Abrego, Garbitt, Victoria, Stein, Caleb, Petit, Joachim, Yuliza, Fonseca, Rodrigo, Todd, Kennedi, Brown, Sochilt, Leonard, Warren, Lonial, Sagar, Bahlis, Nizar, Neri, Paola, Kuehl, W. Michael, Boise, Lawrence, Chesi, Marta, Bergsagel, Leif

Get full text

The VkMYC Mouse Model of Myeloma Identifies Successful Combination Therapies for the Treatment of Bortezomib Refractory Myeloma Patients by Chesi, Marta, Palmer, Stephen, Garbitt, Victoria, Bergsagel, P. Leif

Get full text